US Bancorp DE trimmed its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 12.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 83,470 shares of the company’s stock after selling 12,249 shares during the quarter. US Bancorp DE’s holdings in Sanofi were worth $4,499,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in the business. SRS Capital Advisors Inc. raised its position in Sanofi by 289.1% in the 1st quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock worth $25,000 after purchasing an additional 344 shares during the period. Fairfield Bush & CO. bought a new position in Sanofi in the 1st quarter worth about $26,000. Eagle Bay Advisors LLC bought a new position in Sanofi in the 2nd quarter worth about $28,000. Disciplined Investments LLC grew its stake in Sanofi by 2,270.8% in the 1st quarter. Disciplined Investments LLC now owns 569 shares of the company’s stock worth $31,000 after acquiring an additional 545 shares in the last quarter. Finally, Norwood Financial Corp bought a new position in Sanofi in the 2nd quarter worth about $31,000. 10.06% of the stock is currently owned by hedge funds and other institutional investors.
Sanofi Price Performance
NASDAQ SNY opened at $46.50 on Tuesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.81 and a current ratio of 1.21. The firm’s 50 day moving average price is $51.05 and its 200-day moving average price is $52.21. Sanofi has a 52-week low of $42.63 and a 52-week high of $57.82. The company has a market cap of $117.62 billion, a PE ratio of 14.58, a P/E/G ratio of 2.04 and a beta of 0.60.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on SNY shares. Stifel Nicolaus downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Berenberg Bank upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 5th. Finally, StockNews.com started coverage on shares of Sanofi in a research note on Thursday, October 5th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $60.00.
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
- Five stocks we like better than Sanofi
- How to Invest in Social Media
- Safeguard your portfolio with these three bargain stocks
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Membership clubs gain leverage for the consumer rebound
- Why Invest in High-Yield Dividend Stocks?
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.